Tag: MeRes100 BRS

MeRes100 BRS – the World’s First Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffold – Shows Consistent Long-term Positive Safety With Consistent Low MACE rates and Zero Scaffold Stent Thrombosis for Patients With Coronary Artery Disease

Coronary/Structural Heart by 0 comments

LONDON, July 11, 2019 /PRNewswire/ — Meril’s recently CE-approved MeRes100, used for the treatment of de-novocoronary artery lesions, has demonstrated zero scaffold thrombosis and very low Major Adverse Cardiac Event (MACE) rate of 1.87% at three years as shown in MeRes-1 and 1.61% in MeRes-1 Extend at two years. “First generation bioresorbable scaffolds have not […]

Continue Reading →